THE RECOVERY PEPTIDES
BPC-157 vs. TB-500 — Differences, Evidence, and Why They Are Combined
By G1 Peptides · Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026 · 2 min read
THE SHORT ANSWER
BPC-157 and TB-500 are both studied for tissue repair, but they work differently. BPC-157 is a short gastric peptide studied mainly for tendon, ligament and gut healing, dosed daily. TB-500 is based on thymosin beta-4, promotes cell migration, and is dosed once or twice a week. Neither is FDA-approved, and they are often combined because their mechanisms are thought to complement each other.
At a glance
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | A 15-amino-acid peptide derived from a protein in gastric juice | A synthetic peptide based on thymosin beta-4 |
| Main mechanism | Blood-vessel growth and growth-factor signalling | Actin binding and cell migration |
| Most studied for | Tendon, ligament, muscle and gut healing | Soft tissue, skin, eye and heart repair |
| Typical schedule | Once or twice daily | Once or twice weekly |
| Half-life | Under 30 minutes in animal data | Hours |
| FDA status | Not approved | Not approved |
For a live side-by-side view, including blends, use the comparison tool.
How BPC-157 works
BPC-157 is a stable fragment of a protective protein found in the stomach. In animal studies it increases the formation of new blood vessels and the activity of growth-factor pathways at the site of an injury (Sikiric 2011). That matters most in tissue with a poor blood supply, such as tendon, which is where its strongest animal data sits (Chang 2011).
Read the full profile: What is BPC-157?
How TB-500 works
TB-500 is modelled on thymosin beta-4, a protein present in almost every human cell. It binds actin, part of the internal skeleton that lets cells move. More mobile repair cells reach an injury faster, and the peptide also promotes new blood vessels and reduces inflammation (Goldstein 2012).
Read the full profile: What is TB-500?
Where the evidence differs
Both peptides rest mostly on animal and laboratory studies. Neither has a controlled human trial for the sports and recovery uses they are known for.
- BPC-157 has the larger body of animal work on tendon, ligament and gut injury. Most of it comes from one research group, so independent confirmation is limited.
- TB-500 has human trial work on thymosin beta-4 itself, in wound and eye healing, which gives it somewhat more human safety data.
A provider who prescribes either should be able to tell you this plainly.
Why they are combined
The two act on different steps of repair: BPC-157 on blood supply and growth factors, TB-500 on getting cells to the site. That is the reasoning behind prescribing them together, and behind blends that put both in one preparation. The reasoning is plausible, but the combination has not been tested in a controlled human trial.
Blends also change the practical side: one injection instead of two, at a fixed ratio. See the BPC-157 + TB-500 profile.
Side effects
Both are generally reported as well tolerated. Injection-site reactions are the most common complaint. TB-500 is also associated with temporary tiredness or headache. Long-term safety in people has not been established for either. See peptide side effects and safety.
FREQUENTLY ASKED
Which is better, BPC-157 or TB-500?
Neither is better in general. They have not been compared head to head in a human trial. BPC-157 has more animal data for tendon, ligament and gut injuries. TB-500 has more for soft tissue, skin and heart tissue. Which fits depends on the injury, and that is a decision for a provider.
Can you take BPC-157 and TB-500 together?
Yes, they are commonly prescribed together, and blends that combine both in one vial or pen exist. The combination has not been tested in a controlled human trial, so the case for it rests on the two having different mechanisms.
Is BPC-157 or TB-500 FDA-approved?
No. Neither is approved by the FDA for any use, and both are prohibited in competitive sport by the World Anti-Doping Agency.
How are the doses different?
BPC-157 is usually described at 200 to 500 mcg once or twice a day. TB-500 is usually described at 2 to 2.5 mg twice a week during a loading phase, then less often. A provider sets the actual dose.
SOURCES
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 — novel therapy in gastrointestinal tract. Current Pharmaceutical Design (2011)
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (2011)
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4 — a multi-functional regenerative peptide. Expert Opinion on Biological Therapy (2012)
This article is educational and is not medical advice. Peptides are prescription medications; whether any of them is appropriate for you is a decision for a licensed provider who knows your history.